Published On: Wed, Oct 19th, 2016

New Analyst Ratings On Immunomedics, Inc. (IMMU)


Recently stock market analysts have updated their consensus ratings on shares of Immunomedics, Inc. (IMMU).

Most recent broker ratings

10/06/2016 – Immunomedics, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 5.5 price target on the stock.

06/21/2016 – Immunomedics, Inc. was downgraded to “market perform” by analysts at Wells Fargo.

07/29/2015 – Immunomedics, Inc. had its “outperform” rating reiterated by analysts at Oppenheimer.

09/30/2014 – Immunomedics, Inc. had its “buy” rating reiterated by analysts at Panmure Gordon. They now have a USD 150 price target on the stock.

08/27/2014 – Immunomedics, Inc. was downgraded to “neutral” by analysts at R. F. Lafferty. They now have a USD 4 price target on the stock.

01/08/2014 – Chardan Capital began new coverage on Immunomedics, Inc. giving the company a “buy” rating. They now have a USD 9 price target on the stock.

Immunomedics, Inc. has a 50 day moving average of 2.89 and a 200 day moving average of 3.03. The stock’s market capitalization is 208.03M, it has a 52-week low of 1.61 and a 52-week high of 5.44.

The share price of the company (IMMU) was down -2.25% during the last trading session, with a high of 2.30 and the volume of Immunomedics, Inc. shares traded was 1224132.

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.